Remove Biosimilars Remove Compounding Remove HIV Treatment and Prevention Agents
article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. Zanubrutinib demonstrated sustained efficacy in CLL with del(17p), emphasizing the importance of BTK inhibitors in high-risk hematologic malignancies.

article thumbnail

Educate Patients About Safe Medication Disposal

Pharmacy Times

Image credit: OM | stock.adobe.com Why Proper Disposal Matters Disposing of medications appropriately helps prevent environmental contamination of water and soil. Safe disposal options include DEA Take Back Days, pharmacy kiosks, law enforcement kiosks, mail-back envelopes, and home disposal methods.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.

article thumbnail

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1. December 21, 2004. Subscribe Now!

article thumbnail

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Pharmacy Times

The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.

article thumbnail

Infliximab Biosimilar Initiation Has Increased in Pediatric IBD, Study Finds

Pharmacy Times

Anti-TNFs remain the only FDA-approved class for pediatric IBD, prompting biosimilar use for cost and accessibility. Anti-TNFs remain the only FDA-approved class for pediatric IBD, prompting biosimilar use for cost and accessibility. SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.